(Reuters) – A subsidiary of India’s Sun Pharmaceutical Industries Ltd said on Friday it had donated 2.5 million hydroxychloroquine sulfate tablets in the United States as a potential treatment for coronavirus.
The move comes as healthcare experts meet the growing patient demands for this product as they assess its potential to treat COVID-19 through clinical trials, Sun Pharmaceutical Industries Inc USA said.
(Reporting by Nivedita Balu in Bengaluru; Editing by Maju Samuel)
